Pfizer Inc, C4901001, Phase 1A/B, Open Label, Melanoma ,Solid Tumor, PF-07799544

What is the Purpose of this Study?

-Primary Objective: This is a first-in-human, open-label, Phase 1a/b master protocol to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of PF-07799544 (also known as ARRY-134) as a single agent and in combination with other targeted agents in participants with advanced solid tumors. PF-07799544 (also known as ARRY-134) is a highly selective brain-penetrant small molecule inhibitor of MEK1/2 that is being investigated in participants with advanced solid tumors. -Secondary Objective To characterize the single and multiple-dose PK of PF-07799544 as a single agent. To evaluate preliminary antitumor activity of PF-07799544 as a single agent.


Eligibility

  • * Diagnosis of advanced/metastatic solid tumor including primary brain tumor for monotherapy phase 1a dose escalation
  • * Disease progressed during/following last prior treatment and no satisfactory alternative treatment options for monotherapy phase 1a dose escalation
  • * For Substudy B, histological or cytological diagnosis of advanced/metastatic melanoma
  • * For Substudy C, unresectable or adv/metastatic solid tumor progressed on, or with demonstrated intolerance to SOC, excluding melanoma,
Show more

Where can I participate?

CS Cancer at The Angeles Clinic and Research Institute

More about this Clinical Trial

What is the full name of this clinical trial?

A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH BRAF-MUTANT MELANOMA AND OTHER SOLID TUMORS

Study Details
Disease Type/Condition

Melanoma

Principal Investigator

Mehmi, Inderjit

Co-Investigators

Cathie T Chung, Justin Moyers, Kristopher Wentzel, Navid Hafez, Omid Hamid, Vi K. Chiu

Age Group

Adult

Phase

I/II

IRB Number

STUDY00004014

ClinicalTrials.gov ID

NCT05538130

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Email
clinicaltrials@cshs.org
Study Detail
Disease Type/Condition

Melanoma

Principal Investigator

Mehmi, Inderjit

Age Group

Adult

Phase

I/II

IRB Number

C4901001

ClinicalTrials.gov ID

NCT05538130

Key Eligibility
ClinicalTrials.gov

Contact
Email
clinicaltrials@cshs.org